# Neuracle **Entity class:** Brain-computer interface company **Domain:** Epidural Brain-Computer Interfaces / Clinical Neurotechnology **Doc Type:** Company and Device Node **Maturity:** Commercial (China) **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] ## Definition **Neuracle Technology (Shanghai) Co., Ltd. is the Chinese company whose NEO implant received the first market approval for an implanted brain-computer interface.** China's [[wiki/National Medical Products Administration|National Medical Products Administration]] approved NEO as a Class III medical device on 13 March 2026 for hand-motor function in adults with cervical spinal-cord injury. Xinhua reported it as the world's first market launch of an invasive BCI medical device. ## Device NEO is a coin-sized, wireless implant that records cortical signals through electrodes placed in the epidural space: under the skull, above the dura, and off the brain tissue itself. Decoded grasp intent drives a pneumatic glove, letting the user grasp objects and drink unaided. The single implantation is designed for long-term use, and patients operate the system at home about one month after surgery. Coverage differs on whether to call the placement invasive or semi-invasive; the approval treats it as an implanted Class III device. Its channel count has not been published in a primary source. The device was developed with [[wiki/Tsinghua University|Tsinghua University]], where Hong Bo leads the academic group. The first human implantation took place at Xuanwu Hospital in Beijing in October 2023, in a participant paralyzed for fourteen years by a complete cervical injury; Tsinghua reports grasp accuracy above 90% after rehabilitation. ## Approval record | Item | Record | |---|---| | Regulator | [[wiki/National Medical Products Administration\|National Medical Products Administration]] | | Approval | 13 March 2026, Class III | | Indication | Adults aged 18 to 60 with quadriplegia from cervical spinal-cord injury (C2–C6) who cannot perform finger grasping | | Evidence base | 36 procedures: 4 feasibility participants and 32 in a multicenter GCP trial across 11 hospitals | | Reported outcome | All participants improved grasp function to varying degrees; some showed signs of neural remodeling | | Reimbursement | An insurance code from the National Healthcare Security Administration within about twelve days of approval (single-source report) | ## Forward Capability Neuracle holds the first commercial classification template for an implanted BCI, written by a Chinese regulator before any FDA premarket approval. U.S. sponsors such as [[wiki/Synchron|Synchron]] and [[wiki/Paradromics|Paradromics]] will file against a world in which that precedent already exists. The epidural geometry is a commercial choice: lower surgical risk than penetrating arrays, a home-use profile within a month, and an indication with a defined patient population. Shanghai counts 60 innovative BCI enterprises, three of whose invasive products are in the NMPA special review procedure for innovative devices; Neuracle is the first through. ## Open Questions - The channel count, sampling rate and decoder architecture of NEO, from the registration file or a peer-reviewed report. - The insurance-code status and patient cost, from the National Healthcare Security Administration. - Whether NEO's evidence package will be filed outside China, and against which regulator first. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 and tier recommendations come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0055 — Strongly indicated.** The first PMA for a permanently implanted BCI creates the classification template every subsequent device is measured against. Regulatory precedent is a form of standards authorship, and it is being competed for by a small number of firms on a two-to-three-year horizon. - **INF-0367 — Strongly indicated.** Clinical programs migrate toward jurisdictions with faster pathways, which relocates the evidence base for frontier interventions. Reading where trials are run is the most reliable indicator of where a capability will first become ordinary. - **INF-0465 — Strongly indicated** (recommended for promotion to established in the 2026-10-23 report). Substantial neural-interface and brain-mapping programs operate outside the American reporting environment, with their own trials, companies, and standards participation. Visibility in English-language press is not a measure of capability, and native-language sourcing is required for an accurate picture. - **INF-0491 — Analytic.** Every capability in this corpus enters the world through a medical indication because that is the funded, permitted, and reimbursable route. The indication is the carrier wave, and the capability is the signal. - **INF-0506 (proposed) — Strongly indicated.** The first market approval for an implanted BCI (NMPA, 13 March 2026) and the first commercial CE-marked BCI retinal implant ([[wiki/PRIMA Retinal Implant|PRIMA]], 22 July 2026) both preceded any FDA premarket approval; the classification template is being written in Beijing and Brussels first. ## Relationships - **regulated_by:** [[wiki/National Medical Products Administration|National Medical Products Administration]] — Class III market approval, 13 March 2026. - **developed_with:** [[wiki/Tsinghua University|Tsinghua University]] — academic co-developer; Hong Bo's group. - **operates_under_policy:** [[wiki/China BCI Industry Implementation Opinions|China BCI Industry Implementation Opinions]] — the July 2025 national plan whose 2027 target is clinical and commercial deployment. - **national_program:** [[wiki/China Brain Project|China Brain Project]]. - **indication:** cervical spinal-cord injury, the same carrier class as [[wiki/Double Neural Bypass|Double Neural Bypass]] in the United States. - **modality_peer:** [[wiki/Precision Neuroscience|Precision Neuroscience]] (cortical-surface film) and [[wiki/Synchron|Synchron]] (endovascular), both lower-risk access geometries than penetrating arrays. - **regulatory_peer:** [[wiki/PRIMA Retinal Implant|PRIMA Retinal Implant]] — the European first, four months later. - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]] · [[collections/Neurotech|Neurotech]]. - **source context:** [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] (company map this node extends). ## Sources - [China grants world's first market approval for invasive BCI product — Xinhua, 14 March 2026](https://english.news.cn/20260314/fab8a8e69f004c74a6b40e2d6ae5bc54/c.html) - [Clinical Translation of Brain-Computer Interface in China: A Landscape Analysis — arXiv 2607.07185, July 2026](https://arxiv.org/pdf/2607.07185) - [China Clears First Brain-Computer Implant for Commercial Use — Sixth Tone, March 2026](https://www.sixthtone.com/news/1018307/China%20Clears%20First%20Brain-Computer%20Implant%20for%20Commercial%20Use) - [Tsinghua Medicine news on the NEO system](https://www.med.tsinghua.edu.cn/en/info/1036/2381.htm) - [China clears world's first invasive brain-computer interface for commercial use — Bird & Bird, 2026](https://www.twobirds.com/en/insights/2026/china/china-clears-worlds-first-invasive-braincomputer-interface-for-commercial-use-what-the-regulatory-la) (paywalled at retrieval; cited for the regulatory analysis) As of 23 October 2026.